Advertisement
China’s drug innovators tap AI to quicken discovery, slash costs, win deals
A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition
2-MIN READ2-MIN
Listen
Upstart Chinese drug innovators are joining their foreign competitors in deploying more artificial intelligence (AI) tools to reduce the costs of discoveries in an effort to shorten the route to clinical trials and commercialisation.
Genscript Biotech, based in Nanjing in eastern Jiangsu province, is developing in-house AI tools - using its enzyme prediction database and an algorithm for altering the DNA sequence of a gene - to identify and optimise promising candidates based on protein sequences and therapeutic targets, according to analysts at Jefferies.
XTalPi, a Shenzhen-based AI-powered new drugs research firm, announced on Monday a deal with US firm DoveTree for global commercialisation rights to its drug candidates for multiple oncology, autoimmune and neurological diseases.
Boston-based Insilico Medicine published the results of its phase two trial of rentosertib in the Nature Medicine journal, claiming the first proof-of-concept clinical validation of AI-driven discovery. Its drug candidate was tested for idiopathic pulmonary fibrosis, a chronic and progressive disease characterised by the scarring of lung tissue.
Select Voice
Select Speed
1x
AI-generated voice